Photo of Coleman Lindsley,  MD, PhD

Coleman Lindsley, MD, PhD

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute
Phone: (617) 632-6649

Coleman Lindsley, MD, PhD

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Assistant Professor, Medicine, Harvard Medical School
  • Assistant Professor, Medical Oncology, Dana-Farber Cancer Institute

DF/HCC PROGRAM AFFILIATION

Research Abstract

The primary focus of the Lindsley laboratory is the biology and treatment of myeloid malignancies. We have used detailed genetic analysis of large cohorts of patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) to define genetic pathways of disease ontogeny and to identify mutations that predict overall survival after chemotherapy and stem cell transplantation. We use mouse and cell line models to dissect the mechanistic basis of genetic cooperation during myeloid disease progression, with a specific focus on mutations that cause epigenetic alterations.

Publications

Powered by Harvard Catalyst
  • Lindsley RC. Uncoding the genetic heterogeneity of myelodysplastic syndrome. Hematology Am Soc Hematol Educ Program 2017; 2017:447-452. PubMed
  • Vedula RS, Lindsley RC. Measurement of Residual Disease in Acute Myeloid Leukemia. Curr Hematol Malig Rep 2017; 12:574-581. PubMed
  • Lindsley RC. Mutational complexity in myelodysplasia. Best Pract Res Clin Haematol 2017; 30:290-294. PubMed
  • Morgan EA, Lee MN, DeAngelo DJ, Steensma DP, Stone RM, Kuo FC, Aster JC, Gibson CJ, Lindsley RC. Systematic STAT3 sequencing in patients with unexplained cytopenias identifies unsuspected large granular lymphocytic leukemia. Blood Adv 2018; 1:1786-1789. PubMed
  • Lindsley RC, Saber W, Mar BG, Redd R, Wang T, Haagenson MD, Grauman PV, Hu ZH, Spellman SR, Lee SJ, Verneris MR, Hsu K, Fleischhauer K, Cutler C, Antin JH, Neuberg D, Ebert BL. Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. N Engl J Med 2017.